Volume 5.44 | Nov 7

Mammary Cell News 5.44 November 7, 2013
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
Activating ESR1 Mutations in Hormone-Resistant Metastatic Breast Cancer
Through a prospective clinical sequencing program for advanced cancers, scientists enrolled 11 patients with estrogen receptor-positive metastatic breast cancer. Whole-exome and transcriptome analysis showed that six cases harbored mutations of ESR1 affecting its ligand-binding domain, all of whom had been treated with anti-estrogens and estrogen deprivation therapies. [Nat Genet] Abstract | Press Release
Listen Now: New Podcast on ALDH in Breast Cancer Treatment Response
PUBLICATIONS ( Ranked by impact factor of the journal)

Injectable Hydrogels from Triblock Copolymers of Vitamin E-Functionalized Polycarbonate and Poly(ethylene glycol) for Subcutaneous Delivery of Antibodies for Cancer Therapy
Results demonstrated that Herceptin-loaded hydrogel is specific towards HER2-overexpressing cancer cells and cytotoxic action is comparable to that of Herceptin solution. The biocompatibility and biodegradability of hydrogel were evaluated in mice with subcutaneous injection by histological examination. [Adv Funct Mater] Abstract | Press Release

Mitochondrial Retrograde Signaling Induces Epithelial-Mesenchymal Transition and Generates Breast Cancer Stem Cells
Investigators demonstrated that reducing mitochondrial DNA content in human mammary epithelial cells activates the Calcineurin-dependent mitochondrial retrograde signaling pathway, which induces epithelial-to-mesenchymal transition-like reprogramming to fibroblastic morphology, loss of cell polarity, contact inhibition and acquired migratory and invasive phenotype. [Oncogene] Abstract | Press Release

Inhibition of c-Src Blocks Estrogen-Induced Apoptosis and Restores Estrogen-Stimulated Growth in Long-Term Estrogen-Deprived Breast Cancer Cells
To mimic the clinical administration of c-Src inhibitors, the authors treated cells with either estrogen (E2), a c-Src inhibitor PP2, or the combination for 8 weeks to explore the apoptotic potential of the c-Src inhibitor and E2 on MCF-7:5C cells. [Eur J Cancer] Abstract

Myc Is Required for β-Catenin-Mediated Mammary Stem Cell Amplification and Tumorigenesis
Microarray analysis was used to compare K5ΔNβcat mouse tumors to human breast tumors, mammary cancer cell lines and the tumors developed in other mouse models. Cre-Lox approach was employed to delete Myc from the mammary basal cell layer of K5ΔNβcat mice. Stem cell amplification in K5ΔNβcat mouse mammary epithelium was assessed with 3D-culture and transplantation assays. [Mol Cancer]
Full Article

The Insulin Receptor Plays an Important Role in Secretory Differentiation in the Mammary Gland
In an acinar preparation from mammary epithelial cells isolated from pregnant mice, insulin stimulated lumen formation, mammary cell size, acinar size, acinar casein content, and the formation of lipid droplets with a Km of ~1.7 nM. IGF-I and IGF-II had no effect at concentrations below 50 nM, and a function blocking antibody to the IGF type 1 receptor did not alter the response to insulin. [Am J Physiol-Endocrinol Metab] Abstract

RAGE-Binding S100A8/A9 Promotes the Migration and Invasion of Human Breast Cancer Cells through Actin Polymerization and Epithelial-Mesenchymal Transition
Researchers report for the first time that S100A8/A9 promoted the invasion of breast cancer cells depending on receptor for advanced glycation end products (RAGE). In addition, RAGE binding to S100A8/A9 promoted the phosphorylation of LIN-11, Isl1, and MEC-3 protein domain kinase, as well as cofilin. This phosphorylation is a critical step in cofilin recycling and actin polymerization. [Breast Cancer Res Treat] Abstract

27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth
Investigators report that the cholesterol metabolite 27-hydroxycholesterol (27HC) stimulates MCF-7 cell xenograft growth in mice. More importantly, in estrogen receptor (ER)+ breast cancer patients, 27HC content in normal breast tissue was increased compared to that in cancer-free controls, and tumor 27HC content was further elevated. [Cell Rep] Abstract | Graphical Abstract | Press Release


Lapatinib as a Component of Neoadjuvant Therapy for HER2-Positive Operable Breast Cancer: An Open-Label, Randomized Phase III Trial
The authors studied the effect on tumor response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly paclitaxel after doxorubicin plus cyclophosphamide treatment, and of the addition of lapatinib and trastuzumab combined after doxorubicin plus cyclophosphamide treatment in patients with HER2-positive operable breast cancer to determine whether there would be a benefit of dual HER2 blockade in these patients. [Lancet Oncol] Abstract

Phase II Randomized Trial of Weekly and Every-3-Week Ixabepilone in Metastatic Breast Cancer Patients
This multicenter, open-label, randomized phase II trial compared the efficacy and tolerability of weekly ixabepilone versus the standard 3 weekly dosing regimen. Patients with human epidermal growth factor receptor 2-negative, metastatic breast cancer were randomly assigned to receive either ixabepilone 16 mg/m2 as a 1-hour intravenous (IV) infusion weekly on days 1, 8, and 15 of a 28-day cycle, or 40 mg/m2 as a 3-hour IV infusion on day 1 of a 21-day cycle, until disease progression or unacceptable toxicity. [Breast Cancer Res Treat] Abstract

Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
Breakthroughs in Research and Treatment of Early Breast Cancer: An Overview of the Last Three Decades
This review summarizes the 10th Biedenkopf meeting that was held to review the advances in breast cancer understanding and treatment. [Arch Gynecol Obstet] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.
Pfizer Pharmaceutical Selects Southern Cancer Center as First Site for International Clinical Trial
Pfizer Pharmaceutical has chosen Southern Cancer Center (SCC) as the first treatment center to participate in its PALOMA-III clinical trial, which is an international study for women with metastatic breast cancer. On October 7, the study’s first patient in the U.S. was enrolled at SCC. Throughout the life of the study, Pfizer will enroll 417 participants worldwide. [Southern Cancer Center] Press Release

Queensland, Emory Research Alliance Targets Cancer Treatments
A collaborative research project aimed at discovering a drug to treat a highly resistant form of breast cancer is one of two projects given the green light by the Queensland Emory Development Alliance. [The University of Queensland] Press Release

Lightpoint Medical and Sagentia win £125k Award in TSB Photonics for Health Competition
Lightpoint Medical and Sagentia Technology & Product Development announced that they have jointly received a grant award in the Photonics for Health Competition sponsored by the UK’s innovation agency, the Technology Strategy Board. The award recognizes “projects that apply innovative photonics technologies to challenges in the health sector.” The grant of £125,000 will be used to develop Lightpoint’s molecular imaging technology for breast cancer surgery. [Lightpoint Medical] Press Release

KIYATEC Awarded National Cancer Institute Contract to Establish Predictive 3D Breast Cancer Model
KIYATEC Inc. announced that the National Cancer Institute awarded the company an approximately $295,000 Phase I Small Business Innovation Research contract to establish 3D breast cancer models using living cells obtained directly from breast cancer patients. [KIYATEC Inc.] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Breast Cancer Symposium 2014
September 4-6, 2014
San Francisco, United States

Visit our events page to see a complete list of events in the mammary cell community.
NEW Postdoctoral Fellow – Breast Cancer Stem Cell Biology (UC – College of Medicine)

Clinical Trial Manager – Clinical Trials and Statistics Unit (Institute of Cancer Research)

Research Assistant – BREAST-PREDICT (National University of Ireland Galway)

Postdoctoral Position – Breast Cancer Research (Karolinska Institute)

Postdoctoral Position – Breast Cancer Research (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology and Cancer Genomics (Albert Einstein College of Medicine)

Postdoctoral Position – Computational Biology of Cancer (Gustave Roussy Cancer Institute)

PhD Position – Breast Cancer Bone Metastasis Formation (Claude Bernard University Lyon 1)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Mammary Cell News: Archives | Events | Contact Us